MS and Demyelinating Disorders

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is general neurology.

The study added to the evidence base for recommending adherence to treatment with disease-modifying therapies in clinical practice, a key element for reducing moderate or severe relapse rate.

With the first approved biosimilar entering the US treatment market, the time for clinicians to understand the coming era of therapies is now.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 24, 2023.

The effect of gaslighting on patients can result in serious harms, and although it is potentially common in the MS care continuum, whether it is deliberate or an institutional problem, it must be called out by providers.

We are closer than ever to individualized management of MS, and keeping up with the rapidly changing pace of MS care is challenging even for an MS specialist.

Rebecca Whitney, associate director of Programs and Community Support at SRNA and mother of child with a rare neuroimmune disorder, provided thoughts on the importance of caregivers and the role they play in everyday life.

The physician neurologist and neuroimmunologist at Cedars Sinai Medical Center discussed RNDS 2023, an educational event for Spanish-speaking patients with rare neuroimmune disorders.

Pixyl.Neuro, a CE-marked medical device, is designed to be integrated into the radiology workflow, providing clinicians with diagnostic support of neuroinflammatory and neurodegenerative disorders.

Neurology experts discuss safety data for BTKIs.

Jiwon Oh, MD, PhD, FRCPC, provides an overview of phase II results of tolebrutinib for the treatment of multiple sclerosis.

A recently published study revealed that speech markers can have a high accuracy in distinguishing between neurodegenerative diseases and healthy speech, emphasizing the significance of speech analysis in disease assessment.

A recent study conducted across 11 centers globally challenged the assumption that cognitive rehabilitation and exercise synergistically benefit patients with progressive multiple sclerosis.

Insurance coverage or cost was considered a barrier to prescribing novel NMOSD treatments in 42% of respondents, with the highest rate seen in eculizumab.

Here's some of what is coming soon to NeurologyLive® this week.

Neurology News Network for the week ending November 18, 2023. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 17, 2023.

The physician neurologist and neuroimmunologist at Cedars Sinai Medical Center detailed the difficulties with discussing neuroimmune disorders with newly diagnosed patients, including those who may not speak English. [WATCH TIME: 3 minutes]

The multiple sclerosis (MS) experts advise health care providers on how to impact the early onset of disease progression and prevent neurodegeneration in patients with MS.

The neurologists discuss strategies to improve the cognitive health of patients with multiple sclerosis through physical and mental health multidisciplinary care.

Most of the studies included highlighted the increasing level of difficulty in all exercises performed and that the transition from one kinematic protocol to the other depended on the patient’s rate of improvement.

The associate professor in the department of neurology and neurosurgery at McGill University discussed results from a study on the long-term use of continuous positive airway pressure treatment among patients with multiple sclerosis and sleep apnea presented at MSMilan 2023. [WATCH TIME: 5 minutes]

A recent meta-analysis on tocilizumab in neuromyelitis optica spectrum disorder (NMOSD) emphasized its effectiveness in reducing relapse rates and improving patient function, with patient-specific factors influencing outcomes.

The physician neurologist and neuroimmunologist at Cedars Sinai Medical Center provided perspective on the patient-clinician relationships and the need to educate clinicians about the impacts of rare neuroimmune disorders in Spanish-speaking communities. [WATCH TIME: 3 minutes]

Neurofilament light, a marker of neuroaxonal damage, is correlated with increased levels of disease progression and clinical relapses.